Brief: Inhibrx To Host Webcast Presentation Of Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And To Provide Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts
22/10/2025 22:37
Oct 22 (Reuters) - Inhibrx Biosciences Inc INBX.O: INHIBRX TO HOST WEBCAST PRESENTATION OF TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND TO PROVIDE UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTS Source text: ID:nPn45h7Hna Further company coverage: INBX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibrx Biosciences
See all newsInhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study (updated)
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
NASDAQ RESUMED AT 08:00 AM
Brief: Inhibrx's Inbrx-106 Nearly Doubles Response Rate And Achieves Interim Median Pfs Of 9.6 Months In Phase 2 Hnscc Study
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM